REPL Replimune Group, Inc.
Legal ·
The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action.
The Third Amendment raises the third tranche to $35 million, which was funded at closing, and sets the interest rate at the greater of 8.50% or Prime plus 1.75%. Replimune says its cash runway now reaches late into the first quarter of 2027.
Replimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024.
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | $221.2 million | $189.4 million |
| Net income (loss) | -$313.9 million | -$247.3 million |
| Cash from operations | -$280.3 million | -$192.2 million |
| Cash and equivalents | $209.0 million | $111.1 million |
| Short-term investments | $59.9 million | $372.7 million |
Our latest story on this, dated Oct 28, 2026: "Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits". The story links the filing or release it is based on. Read the story.
Replimune Group, Inc. trades under the ticker REPL on NASDAQ.
Replimune Group, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:7R8; LS:A2JQN1.
The SEC Central Index Key (CIK) for Replimune Group, Inc. is 1737953. Its filings are on SEC EDGAR.
94,219,634 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Replimune Group, Inc. under United States.
Our directory classifies Replimune Group, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Replimune Group, Inc. is US76029N1063.
aibio.space lists Replimune Group, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Replimune Group, Inc. reported a net loss of $313.9 million for the fiscal year ended Mar 31, 2026, and used $280.3 million of cash in operations, per its annual report to the SEC.
$221.2 million in the fiscal year ended Mar 31, 2026, per its annual report.
$307.8 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.
Our latest story on Replimune Group, dated Oct 28, 2026: "Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits". The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action. Source.
Our latest financing story, dated Mar 7, 2025: "Replimune adds Baker Bros. employee to board, grants BBA Funds resale registration rights". Replimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio